These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28166468)

  • 1. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
    Zhou H; Chen C; Sun L; Zeng Z
    Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
    Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
    Sato H; Hirakawa A; Hamada C
    Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose finding methods for targeted agents: new perspectives].
    Paoletti X; Postel-Vinay S; Servois V; Doussau A; Ollivier L; Le Tourneau C
    Bull Cancer; 2010 Dec; 97(12):1485-95. PubMed ID: 21220226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
    Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
    Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.